1. Home
  2. SLXNW
  3. SLXNW News

Latest Biomotion Sciences Warrant (SLXNW) News on December 18, 2024

Silexion Therapeutics, Evonik collaborate on siRNA formulation development
SLXNW

TipRanks

12 hours ago

Silexion Therapeutics, Evonik collaborate on siRNA formulation development

PESG Releases Market Update: Silexion Therapeutics Advances KRAS-Targeting Therapies with New Collaboration As Industry Demand for Precision Oncology Solutions Rises
SLXNW

Business Wire

a day ago

PESG Releases Market Update: Silexion Therapeutics Advances KRAS-Targeting Therapies with New Collaboration As Industry Demand for Precision Oncology Solutions Rises

Silexion Therapeutics collaborates with Evonik on advanced siRNA Formulation Development
SLXNW

GlobeNewswire

2 days ago

Silexion Therapeutics collaborates with Evonik on advanced siRNA Formulation Development

Silexion Therapeutics Appoints Renowned Cancer Therapeutics Expert Prof. Amnon Peled to Board of Directors
SLXNW

GlobeNewswire

8 days ago

Silexion Therapeutics Appoints Renowned Cancer Therapeutics Expert Prof. Amnon Peled to Board of Directors

Silexion Therapeutics Announces 1-for-9 Reverse Share Split
SLXNW

GlobeNewswire

a month ago

Silexion Therapeutics Announces 1-for-9 Reverse Share Split

Silexion Therapeutics to Present at the Noble Capital Markets 20th Annual Emerging Growth Equity Conference
SLXNW

GlobeNewswire

a month ago

Silexion Therapeutics to Present at the Noble Capital Markets 20th Annual Emerging Growth Equity Conference

SLXNW

ACCESSWIRE

a month ago

Silexion Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

SLXNW

ACCESSWIRE

2 months ago

Silexion Therapeutics to Present at 2024 Maxim Healthcare Virtual Summit

Silexion Therapeutics Reports Breakthroughs From SIL-204 Preclinical Studies
SLXNW

Business Wire

3 months ago

Silexion Therapeutics Reports Breakthroughs From SIL-204 Preclinical Studies

Silexion Therapeutics Announces Significant New Data from Phase 2 Trial of LODER™ in Non-Resectable Pancreatic Cancer
SLXNW

Business Wire

3 months ago

Silexion Therapeutics Announces Significant New Data from Phase 2 Trial of LODER™ in Non-Resectable Pancreatic Cancer

PESG Releases Report on Silexion Therapeutics: Pioneering RNAi Technology in the Fight Against KRAS-Driven Cancers
SLXNW

Business Wire

3 months ago

PESG Releases Report on Silexion Therapeutics: Pioneering RNAi Technology in the Fight Against KRAS-Driven Cancers

Silexion Therapeutics to Present at the H.C. Wainright 26th Annual Global Investment Conference
SLXNW

GlobeNewswire

3 months ago

Silexion Therapeutics to Present at the H.C. Wainright 26th Annual Global Investment Conference

Share on Social Networks: